This highly positive ROR1 membrane profile in CLL and HCL could help to avoid patient selection for trial recruitment in case ROR1 is used as tumour target for ADC, TCE, or CAR-T development [1, 10]. This evidence concerns the gene ROR1 and B-cell chronic lymphocytic leukemia.